Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Shopify Inc. (SHOP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Shopify Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Shopify Inc. trades at $167.03 (market cap $221.95B). The key difference: Shopify Inc. is far larger — about 227.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Shopify Inc. is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Shopify Inc. for 78 Days on average.
| MRVI | SHOP | |
|---|---|---|
Market Cap | $977.37M | $221.95B |
Volume | 2,742,564 | 8,347,327 |
Sector | Health | Technology |
52-Week High | $9.00 | $179.22 |
52-Week Low | $2.83 | $95.40 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $1.08B | $217.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Shopify trades at $176.43, down 1.56% on the day, with strong technical momentum showing bullish moving averages despite overbought RSI readings. The company demonstrates robust revenue growth from $5.6B in 2022 to $11.6B in 2025, with net income turning positive at $1.23B. Recent developments include the launch of Canvas AI store-building tool and strategic moves in AI-powered commerce positioning.
Shopify presents a compelling growth story with accelerating merchant solutions and subscription revenues, though valuation multiples remain elevated. Key risks include competitive pressures from Amazon and execution challenges in AI integration. Analyst consensus remains bullish with 67% buy ratings, though the current price sits near the consensus target of $174.58.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
